Pomerantz LLP is investigating claims on behalf of investors of The Ensign Group, Inc. regarding potential securities fraud or unlawful business practices. The investigation follows a June 8, 2026 short report by Hunterbrook alleging that Ensign Group's business model relies on inadequate patient care and gaming quality metrics, causing the stock to fall $13.88 per share, or 8.15%, to close at $156.42. On June 11, 2026, Muddy Waters Research published another short report alleging possible Medicare and Medicaid fraud, leading to a further decline of $4.52 per share, or 2.98%, to close at $147.13. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The Ensign Group IncShort-seller allegations of Medicare/Medicaid fraud and inadequate patient care, leading to stock price declines.